IFNγ-10 mRNA Assay for Tuberculosis in HIV/AIDS – China Study
- tuberculosis (TB) remains a important global health threat, especially for individuals living with Human Immunodeficiency Virus (HIV).
- Researchers evaluated the Interferon Gamma-Induced Protein 10 (IP-10) mRNA Release assay as an aid in diagnosing tuberculosis.
- The study, conducted between 2022 and 2024 in Beijing, focused on individuals living with HIV/AIDS.
Improving Tuberculosis Diagnosis in Vulnerable Populations
Table of Contents
Published: August 22, 2025
The Challenge of TB and HIV Co-infection
tuberculosis (TB) remains a important global health threat, especially for individuals living with Human Immunodeficiency Virus (HIV). People with HIV are significantly more likely to develop active TB disease, making accurate and timely diagnosis crucial. Customary diagnostic methods can be limited in sensitivity, especially in those with advanced HIV infection. A recent study from Beijing Municipality, China, investigated the potential of a new diagnostic tool to improve TB detection in this vulnerable population.
Introducing the IP-10 mRNA Release Assay
Researchers evaluated the Interferon Gamma-Induced Protein 10 (IP-10) mRNA Release assay as an aid in diagnosing tuberculosis. IP-10 is a chemokine – a type of signaling protein – known to be upregulated in response to Mycobacterium tuberculosis infection.The assay measures the amount of IP-10 mRNA released by immune cells when exposed to TB-specific antigens. This approach offers a possibly more sensitive and rapid method for identifying individuals with latent or active TB infection.
Study Findings in Beijing
The study, conducted between 2022 and 2024 in Beijing, focused on individuals living with HIV/AIDS. Researchers compared the performance of the IP-10 mRNA assay to traditional diagnostic methods, including sputum smear microscopy and culture. the results indicated that the IP-10 mRNA assay demonstrated a valuable auxiliary diagnostic role, particularly in cases where conventional methods were inconclusive. The assay helped identify individuals with TB who might have been missed by standard testing.
Why This Matters for Global Health
Accurate TB diagnosis is the first step toward effective treatment and preventing further transmission. For people living with HIV, a delayed diagnosis can have devastating consequences. The IP-10 mRNA assay offers a promising tool to improve diagnostic accuracy, especially in resource-limited settings where access to advanced laboratory facilities may be limited. The World Health Organization estimates that 10.6 million people fell ill with TB globally in 2022.
Understanding Tuberculosis
Tuberculosis is caused by the bacterium mycobacterium tuberculosis. The disease typically affects the lungs, but can also spread to other parts of the body, such as the kidneys, spine, and brain.TB is spread through the air when a person with active TB disease coughs, speaks, or sings, releasing tiny droplets containing the bacteria. There are two main forms of TB: latent TB infection, where the bacteria are present but inactive, and active TB disease, where the bacteria are multiplying and causing symptoms. The Centers for Disease Control and Prevention (CDC) provides complete data on understanding tuberculosis.
The Link Between TB and HIV
HIV weakens the immune system, making individuals more susceptible to opportunistic infections like TB. People with HIV are estimated to have a 13% lifetime risk of developing TB, compared to a 0.1% risk for those without HIV. TB is a leading cause of death among people living with HIV. Early diagnosis and treatment of both TB and HIV are crucial for improving health outcomes.